TY - JOUR
T1 - Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy
T2 - A REL (Rete Ematologica Lombarda) experience
AU - Arcaini, Luca
AU - Laszlo, Daniele
AU - Rizzi, Silvia
AU - Balzarotti, Monica
AU - Antoniazzi, Francesca
AU - Zilioli, Vittorio Ruggero
AU - Guggiari, Elena
AU - Farina, Lucia
AU - Todisco, Elisabetta
AU - Bonfichi, Maurizio
AU - Alamos, Sara Miqueleiz
AU - Rossi, Giuseppe
AU - Martinelli, Giovanni
AU - Morra, Enrica
PY - 2011/6
Y1 - 2011/6
N2 - Plerixafor has been previously reported to improve PBSC collection in pts undergoing PBSC mobilization. Aim of the study was to assess the efficacy of plerixafor and G-CSF in pts with lymphoma who failed previous attempts of PBSC mobilization with conventional schemes of chemotherapy+G-CSF. 35 heavily pre-treated lymphoma pts (29 NHL, 6 HL) classified as " poor mobilizers" were enrolled in a program of compassionate use of plerixafor in 7 Italian centres of REL (Rete Ematologica Lombarda). Median number of previous lines of therapy was 3 and median number of previous attempts of mobilizations was 2. The median number of circulating CD34+ cells/μL following plerixafor was 11/μL. It was ≥10/μL in 17 pts and ≥20/μL in 10 pts; 13 were able to collect ≥2×10 6 CD34+ cells/kg with a median of 1 apheresis procedure; 4 pts collected ≥4×10 6 CD34+ cells/kg. A total of 6 pts had proceeded to transplant at the time of analysis. The median dose of PBSCs infused was 4×10 6/kg and hematopoietic recovery was regular. In conclusion, plerixafor combined with G-CSF allows a collection of adequate number of PBSC in approximately 40% of cases of poor mobilizer, heavily pre-treated pts with lymphoma, who need consolidation with ASCT.
AB - Plerixafor has been previously reported to improve PBSC collection in pts undergoing PBSC mobilization. Aim of the study was to assess the efficacy of plerixafor and G-CSF in pts with lymphoma who failed previous attempts of PBSC mobilization with conventional schemes of chemotherapy+G-CSF. 35 heavily pre-treated lymphoma pts (29 NHL, 6 HL) classified as " poor mobilizers" were enrolled in a program of compassionate use of plerixafor in 7 Italian centres of REL (Rete Ematologica Lombarda). Median number of previous lines of therapy was 3 and median number of previous attempts of mobilizations was 2. The median number of circulating CD34+ cells/μL following plerixafor was 11/μL. It was ≥10/μL in 17 pts and ≥20/μL in 10 pts; 13 were able to collect ≥2×10 6 CD34+ cells/kg with a median of 1 apheresis procedure; 4 pts collected ≥4×10 6 CD34+ cells/kg. A total of 6 pts had proceeded to transplant at the time of analysis. The median dose of PBSCs infused was 4×10 6/kg and hematopoietic recovery was regular. In conclusion, plerixafor combined with G-CSF allows a collection of adequate number of PBSC in approximately 40% of cases of poor mobilizer, heavily pre-treated pts with lymphoma, who need consolidation with ASCT.
KW - Lymphoma
KW - PBSC mobilization
KW - Plerixafor
KW - Poor mobilizers
UR - http://www.scopus.com/inward/record.url?scp=79955584638&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79955584638&partnerID=8YFLogxK
U2 - 10.1016/j.leukres.2010.12.036
DO - 10.1016/j.leukres.2010.12.036
M3 - Article
C2 - 21276613
AN - SCOPUS:79955584638
VL - 35
SP - 712
EP - 714
JO - Leukemia Research
JF - Leukemia Research
SN - 0145-2126
IS - 6
ER -